FBLN2 and neoplasm: In UBUC (Table 4) patients with high FBLN2-expressing tumors, 39.9% had tumor metastasis and 27.0% died of the disease, whereas only 11.6% of patients with low FBLN2-expressing tumors had subsequent metastatic tumors and 8.2% experienced cancer deaths.